Sisram Medical, which markets DAXXIFY (daxibotulinumtoxinA-lanm, a long-acting neuromodulator), has restructured its China distribution agreement with Fosun, a connected entity. The move reflects Sisram's strategy to optimize supply-chain economics and market access in Asia-Pacific, where neuromodulator demand is accelerating but pricing remains highly competitive.